{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T11:36:39Z","timestamp":1763552199617,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T00:00:00Z","timestamp":1656979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81971719"],"award-info":[{"award-number":["81971719"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2021A1515010548"],"award-info":[{"award-number":["2021A1515010548"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013050","name":"Guangdong Provincial Applied Science and Technology Research and Development Program","doi-asserted-by":"publisher","award":["A2020081"],"award-info":[{"award-number":["A2020081"]}],"id":[{"id":"10.13039\/501100013050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1007\/s00432-022-04107-w","type":"journal-article","created":{"date-parts":[[2022,7,5]],"date-time":"2022-07-05T03:27:47Z","timestamp":1656991667000},"page":"1873-1882","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Sorafenib plus drug-eluting bead transarterial chemoembolization for early intrahepatic stage-progressed advanced hepatocellular carcinoma refractory to conventional transarterial chemoembolization"],"prefix":"10.1007","volume":"149","author":[{"given":"Wenzhe","family":"Fan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bowen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shufan","family":"Yue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huishuang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liangliang","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fuliang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guosheng","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanqin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinhua","family":"Zou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-8877","authenticated-orcid":false,"given":"Jiaping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,7,5]]},"reference":[{"key":"4107_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jvir.2011.11.029","volume":"23","author":"DB Brown","year":"2012","unstructured":"Brown DB, Nikolic B, Covey AM et al (2012) Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol 23:287\u2013294. https:\/\/doi.org\/10.1016\/j.jvir.2011.11.029","journal-title":"J Vasc Interv Radiol"},{"key":"4107_CR2","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1002\/hep.20933","volume":"42","author":"J Bruix","year":"2005","unstructured":"Bruix J, Sherman M (2005) Practice guidelines committee, american association for the study of liver diseases management of hepatocellular carcinoma. Hepatology 42:1208\u20131236. https:\/\/doi.org\/10.1002\/hep.20933","journal-title":"Hepatology"},{"key":"4107_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver (2018) EASL clinical practice guidelines easl clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019","journal-title":"J Hepatol"},{"key":"4107_CR4","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin SK, Ikeda M et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905. https:\/\/doi.org\/10.1056\/NEJMoa1915745","journal-title":"N Engl J Med"},{"key":"4107_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.3_suppl.267","author":"RS Finn","year":"2021","unstructured":"Finn RS, Qin SK, Ikeda M et al (2021) IMbrave150: updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) plus bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC). J Clin Oncol 39(3).\u00a0https:\/\/doi.org\/10.1200\/JCO.2021.39.3_suppl.267","journal-title":"J Clin Oncol"},{"key":"4107_CR6","first-page":"3523","volume":"36","author":"M Hatooka","year":"2016","unstructured":"Hatooka M, Kawaoka T, Aikata H et al (2016) Comparison of outcome of hepatic arterial infusion chemotherapy and sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Anticancer Res 36:3523\u20133529","journal-title":"Anticancer Res"},{"key":"4107_CR7","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1159\/000452846","volume":"6","author":"A Hiraoka","year":"2017","unstructured":"Hiraoka A, Kumada T, Kudo M et al (2017) Albumin-bilirubin (ALBI) grade as part of the evidence-based clinical practice guideline for HCC of the Japan society of hepatology: a comparison with the liver damage and child-pugh classifications. Liver Cancer 6:204\u2013215. https:\/\/doi.org\/10.1159\/000452846","journal-title":"Liver Cancer"},{"key":"4107_CR8","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1007\/s00535-013-0853-7","volume":"49","author":"M Ikeda","year":"2014","unstructured":"Ikeda M, Mitsunaga S, Shimizu S et al (2014) Efficacy of sorafenib in patients with hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. J Gastroenterol 49:932\u2013940. https:\/\/doi.org\/10.1007\/s00535-013-0853-7","journal-title":"J Gastroenterol"},{"key":"4107_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/0168-8278(91)90873-a","volume":"13","author":"PJ Johnson","year":"1991","unstructured":"Johnson PJ, Kalayci C, Dobbs N et al (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular carcinoma: effect of coadministration of lipiodol. J Hepatol 13:120\u2013127. https:\/\/doi.org\/10.1016\/0168-8278(91)90873-a","journal-title":"J Hepatol"},{"key":"4107_CR10","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1111\/j.1440-1746.2011.06963.x","volume":"27","author":"HY Kim","year":"2012","unstructured":"Kim HY, Park JW, Joo J et al (2012) Severity and timing of progression predict refractoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol 27:1051\u20131056. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06963.x","journal-title":"J Gastroenterol Hepatol"},{"key":"4107_CR11","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1159\/000343875","volume":"3","author":"M Kudo","year":"2014","unstructured":"Kudo M, Matsui O, Izumi N et al (2014) JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 3:58\u201368. https:\/\/doi.org\/10.1159\/000343875","journal-title":"Liver Cancer"},{"key":"4107_CR12","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1159\/000439290","volume":"33","author":"M Kudo","year":"2015","unstructured":"Kudo M, Arizumi T, Ueshima K, Sakurai T, Kitano M, Nishida N (2015) Subclassification of BCLC B stage hepatocellular carcinoma and treatment strategies: proposal of modified bolondi\u2019s subclassification (kinki criteria). Dig Dis 33:751\u2013758. https:\/\/doi.org\/10.1159\/000439290","journal-title":"Dig Dis"},{"key":"4107_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.4_suppl.368","author":"M Kudo","year":"2018","unstructured":"Kudo M, Paoul J, Lee H et al (2018) Deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): an exploratory analysis of OPTIMIS-an international observational study assessing the use of sorafenib after TACE. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2018.36.4_suppl.368","journal-title":"J Clin Oncol"},{"key":"4107_CR14","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1136\/gutjnl-2019-318934","volume":"69","author":"M Kudo","year":"2020","unstructured":"Kudo M, Ueshima K, Ikeda M et al (2020) Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut 69:1492\u20131501. https:\/\/doi.org\/10.1136\/gutjnl-2019-318934","journal-title":"Gut"},{"key":"4107_CR15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00270-009-9711-7","volume":"33","author":"J Lammer","year":"2010","unstructured":"Lammer J, Malagari K, Vogl T et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the precision V study. Cardiovasc Intervent Radiol 33:41\u201352. https:\/\/doi.org\/10.1007\/s00270-009-9711-7","journal-title":"Cardiovasc Intervent Radiol"},{"key":"4107_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1046\/j.1440-1746.2002.02664.x","volume":"17","author":"JK Lee","year":"2002","unstructured":"Lee JK, Chung YH, Song BC et al (2002) Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol 17:52\u201358. https:\/\/doi.org\/10.1046\/j.1440-1746.2002.02664.x","journal-title":"J Gastroenterol Hepatol"},{"key":"4107_CR17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","volume":"30","author":"R Lencioni","year":"2010","unstructured":"Lencioni R, Llovet JM (2010) Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30:52\u201360. https:\/\/doi.org\/10.1055\/s-0030-1247132","journal-title":"Semin Liver Dis"},{"key":"4107_CR18","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1007\/s00270-011-0287-7","volume":"35","author":"R Lencioni","year":"2012","unstructured":"Lencioni R, de Baere T, Burrel M et al (2012) Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Interv Radiol 35:980\u2013985. https:\/\/doi.org\/10.1007\/s00270-011-0287-7","journal-title":"Cardiovasc Interv Radiol"},{"key":"4107_CR19","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1002\/hep.28453","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF (2016a) Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety data. Hepatology 64:106\u2013116. https:\/\/doi.org\/10.1002\/hep.28453","journal-title":"Hepatology"},{"key":"4107_CR20","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/j.jhep.2016.01.012","volume":"64","author":"R Lencioni","year":"2016","unstructured":"Lencioni R, Llovet JM, Han G et al (2016b) Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J Hepatol 64:1090\u20131098. https:\/\/doi.org\/10.1016\/j.jhep.2016.01.012","journal-title":"J Hepatol"},{"key":"4107_CR21","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.acra.2019.07.003","volume":"27","author":"J Liu","year":"2020","unstructured":"Liu J, Xu J, Zhang W et al (2020) Safety and efficacy of drug-eluting bead transarterial chemoembolization combined with apatinib in patients with advanced hepatocellular carcinoma. Acad Radiol 27:704\u2013709. https:\/\/doi.org\/10.1016\/j.acra.2019.07.003","journal-title":"Acad Radiol"},{"key":"4107_CR22","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S2468-1253(17)30156-5","volume":"2","author":"T Meyer","year":"2017","unstructured":"Meyer T, Fox R, Ma YT et al (2017) Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol 2:565\u2013575. https:\/\/doi.org\/10.1016\/S2468-1253(17)30156-5","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"4107_CR23","unstructured":"National Cancer Institute, National Institutes of Health (2017) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 Published: November 27, 2017 U.S. Department Of Health And Human Services. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 31 Aug 2021."},{"key":"4107_CR24","doi-asserted-by":"publisher","first-page":"251","DOI":"10.4143\/crt.2014.011","volume":"47","author":"D Oh","year":"2015","unstructured":"Oh D, Shin SW, Park HC, Cho SK, Lim DH, Paik SW (2015) Changes in arterioportal shunts in hepatocellular carcinoma patients with portal vein thrombosis who were treated with chemoembolization followed by radiotherapy. Cancer Res Treat 47:251\u2013258. https:\/\/doi.org\/10.4143\/crt.2014.011","journal-title":"Cancer Res Treat"},{"key":"4107_CR25","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jhep.2012.01.006","volume":"56","author":"JW Park","year":"2012","unstructured":"Park JW, Koh YH, Kim HB et al (2012) Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol 56:1336\u20131342. https:\/\/doi.org\/10.1016\/j.jhep.2012.01.006","journal-title":"J Hepatol"},{"key":"4107_CR26","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.jhep.2018.11.029","volume":"70","author":"JW Park","year":"2019","unstructured":"Park JW, Kim YJ, Kim DY et al (2019) Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: the phase III STAH trial. J Hepatol 70:684\u2013691. https:\/\/doi.org\/10.1016\/j.jhep.2018.11.029","journal-title":"J Hepatol"},{"key":"4107_CR27","doi-asserted-by":"publisher","first-page":"3960","DOI":"10.1200\/JCO.2011.37.1021","volume":"29","author":"TM Pawlik","year":"2011","unstructured":"Pawlik TM, Reyes DK, Cosgrove D, Kamel IR, Bhagat N, Geschwind JF (2011) Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol 29:3960\u20133967. https:\/\/doi.org\/10.1200\/JCO.2011.37.1021","journal-title":"J Clin Oncol"},{"key":"4107_CR28","doi-asserted-by":"publisher","first-page":"S202","DOI":"10.1016\/S0168-8278(18)30614-7","volume":"68","author":"M Peck-Radosavljevic","year":"2018","unstructured":"Peck-Radosavljevic M, Kudo M, Lee HC et al (2018) Real-world data in patients with hepatocellular carcinoma treated with transarterial chemoembolization: the second interim analysis of OPTIMIS. J Hepatol 68:S202\u2013S202. https:\/\/doi.org\/10.1016\/S0168-8278(18)30614-7","journal-title":"J Hepatol"},{"key":"4107_CR29","doi-asserted-by":"publisher","first-page":"E616","DOI":"10.1016\/S0618-8278(19)31229-0","volume":"70","author":"M Peck-Radosavljevic","year":"2019","unstructured":"Peck-Radosavljevic M, Lee H, Kudo M (2019) Practice patterns and outcomes of transarterial chemoembolization in patients with hepatocellular carcinoma who were ineligible and eligible for transarterial chemoembolization at inclusion: global OPTIMIS exploratory analysis. J Hepatol 70:E616\u2013E616. https:\/\/doi.org\/10.1016\/S0618-8278(19)31229-0","journal-title":"J Hepatol"},{"key":"4107_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s00270-011-0176-0","volume":"35","author":"A Seki","year":"2012","unstructured":"Seki A, Hori S (2012) Switching the loaded agent from epirubicin to cisplatin: salvage transcatheter arterial chemoembolization with drug-eluting microspheres for unresectable hepatocellular carcinoma. Cardiovasc Interv Radiol 35:555\u2013562. https:\/\/doi.org\/10.1007\/s00270-011-0176-0","journal-title":"Cardiovasc Interv Radiol"},{"key":"4107_CR31","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1016\/j.jhep.2015.02.010","volume":"62","author":"W Sieghart","year":"2015","unstructured":"Sieghart W, Hucke F, Peck-Radosavljevic M (2015) Transarterial chemoembolization: modalities, indication, and patient selection. J Hepatol 62:1187\u20131195. https:\/\/doi.org\/10.1016\/j.jhep.2015.02.010","journal-title":"J Hepatol"},{"key":"4107_CR32","doi-asserted-by":"publisher","first-page":"89","DOI":"10.5009\/gnl.2013.7.1.89","volume":"7","author":"DS Song","year":"2013","unstructured":"Song DS, Choi JY, Yoo SH et al (2013) DC bead transarterial chemoembolization is effective in hepatocellular carcinoma refractory to conventional transarteral chemoembolization: a pilot study. Gut Liver 7:89\u201395. https:\/\/doi.org\/10.5009\/gnl.2013.7.1.89","journal-title":"Gut Liver"},{"key":"4107_CR33","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"4107_CR34","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1016\/j.ejrad.2008.08.007","volume":"72","author":"TJ Vogl","year":"2009","unstructured":"Vogl TJ, Naguib NNN, Nour-Eldin NE et al (2009) Review on transarterial chemoembolization in hepatocellular carcinoma: palliative, combined, neoadjuvant, bridging, and symptomatic indications. Eur J Radiol 72:505\u2013516. https:\/\/doi.org\/10.1016\/j.ejrad.2008.08.007","journal-title":"Eur J Radiol"},{"key":"4107_CR35","doi-asserted-by":"publisher","first-page":"W562","DOI":"10.2214\/AJR.10.4379","volume":"197","author":"TJ Vogl","year":"2011","unstructured":"Vogl TJ, Lammer J, Lencioni R et al (2011) Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with precision TACE with drug-eluting beads: results from the precision V randomized trial. AJR Am J Roentgenol 197:W562\u2013W570. https:\/\/doi.org\/10.2214\/AJR.10.4379","journal-title":"AJR Am J Roentgenol"},{"key":"4107_CR36","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1186\/s12885-017-3545-5","volume":"17","author":"FX Wu","year":"2017","unstructured":"Wu FX, Chen J, Bai T et al (2017) The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B\/C hepatocellular carcinoma. BMC Cancer 17:645. https:\/\/doi.org\/10.1186\/s12885-017-3545-5","journal-title":"BMC Cancer"},{"key":"4107_CR37","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.2147\/CMAR.S193948","volume":"11","author":"YD Xiao","year":"2019","unstructured":"Xiao YD, Ma C, Zhang ZS, Liu J (2019) Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience. Cancer Manag Res 11:1551\u20131557. https:\/\/doi.org\/10.2147\/CMAR.S193948","journal-title":"Cancer Manag Res"},{"key":"4107_CR38","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1148\/radiol.14131946","volume":"272","author":"K Zhu","year":"2014","unstructured":"Zhu K, Chen J, Lai L et al (2014) Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib\u2014a retrospective controlled study. Radiology 272:284\u2013293. https:\/\/doi.org\/10.1148\/radiol.14131946","journal-title":"Radiology"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-022-04107-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-022-04107-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,13]],"date-time":"2023-04-13T03:48:38Z","timestamp":1681357718000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-022-04107-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["4107"],"URL":"https:\/\/doi.org\/10.1007\/s00432-022-04107-w","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2022,7,5]]},"assertion":[{"value":"4 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declared no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}